"The US Food and Drug Administration (FDA) has approved class-wide labeling changes for all prescription testosterone products, the agency announced today.
New safety information from published literature and case reports on the risks "...
The following adverse reactions in the male have occurred with some androgens:
Fluid and electrolyte disturbances: Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates.
Allergic: Hypersensitivity, including skin manifestations and anaphylactoid reactions.
Vascular disorders: Venous thromboembolism.
Miscellaneous: Inflammation and pain at the site of intramuscular injection.
Drug Abuse And Dependence
Controlled Substance Class
Testosterone is a controlled substance under the Anabolic Steroids Control Act, and DEPO-Testosterone Injection has been assigned to Schedule III.
Read the Depo-Testosterone (testosterone cypionate injection) Side Effects Center for a complete guide to possible side effects
Androgens may increase sensitivity to oral anticoagulants. Dosage of the anticoagulant may require reduction in order to maintain satisfactory therapeutic hypoprothrombinemia.
Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.
Drug/Laboratory Test Interferences
Androgens may decrease levels of thyroxine-binding globulin, resulting in decreased total T4 serum levels and increased resin uptake of T3 and T4. Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 5/28/2015
Additional Depo-Testosterone Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.